800 results on '"Mitchell, Duane A."'
Search Results
52. EXTH-22. AN IND-ENABLED STUDY USING A NOVEL CHECKPOINT BLOCKADE OF LAIR1 FOR GLIOBLASTOMA THERAPY
53. EXTH-35. UNRAVELING THE MECHANISTIC UNDERPINNINGS OF MRNA VACCINE MEDIATED INNATE IMMUNE ACTIVATION AND LYMPHOCYTE TRAFFICKING FOR HIGH-GRADE GLIOMAS
54. 875 CA-4948 alters tumor associated macrophage activity in the tumor microenvironment of murine models of melanoma metastases
55. 772 Novel RNA-nanoparticle vaccine for the treatment of early melanoma recurrence following adjuvant anti-PD-1 antibody therapy
56. A vaccine for glioma
57. Precision therapeutic targets for COVID-19
58. Causes of Organizational Conflict
59. Reponses to Organizational Conflict
60. Abstract PR08: Personalized therapeutic mRNA nano-vaccines are effective across multiple preclinical and translational models of head and neck cancer
61. Figure S7 from Oral IRAK-4 Inhibitor CA-4948 Is Blood-Brain Barrier Penetrant and Has Single-Agent Activity against CNS Lymphoma and Melanoma Brain Metastases
62. Elucidating the cellular mechanisms underlying adoptive cell transfer in models of glioma
63. Data from Oral IRAK-4 Inhibitor CA-4948 Is Blood-Brain Barrier Penetrant and Has Single-Agent Activity against CNS Lymphoma and Melanoma Brain Metastases
64. Sarcosine promotes trafficking of dendritic cells and improves efficacy of anti-tumor dendritic cell vaccines via CXC chemokine family signaling
65. Migration of dendritic cells to the lymph nodes and its enhancement to drive anti-tumor responses
66. Gene-modified dendritic cell vaccines for cancer
67. Analysis of immunobiologic markers in primary and recurrent glioblastoma
68. Association of Suppressive Myeloid Cell Enrichment with Aggressive Oropharynx Squamous Cell Carcinoma
69. Abstract LB203: Targeted inhibition of IRAK-4 with CA-4948 (emavusertib) sensitizes metastatic brain melanoma to anti-PD-1 immune checkpoint blockade
70. Abstract 5114: Development of personalized RNA-based immunotherapeutics for glioblastom
71. Abstract 904: Optimizing CAR T therapy via metabolic engineering for the treatment of glioblastoma
72. Florida-California Cancer Research, Education and Engagement (CaRE2) Health Equity Center: Structure, Innovations, and Initial Outcomes
73. Supplementary Figure 7 from Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma
74. Supplementary Figure 1 from Recognition and Killing of Autologous, Primary Glioblastoma Tumor Cells by Human Cytomegalovirus pp65-Specific Cytotoxic T Cells
75. Supplementary Data from Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination
76. Data from Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma
77. Table S2 from Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma
78. Supplementary Figure 5 from Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma
79. Figure S4 from Cross-talk between T Cells and Hematopoietic Stem Cells during Adoptive Cellular Therapy for Malignant Glioma
80. Supplementary Figure 4 from Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma
81. Supplementary Table 1 and 2 from Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma
82. Figure Legend and Supplementary Figure 1 from Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma
83. Supplementary Data from Immune Escape After Adoptive T-cell Therapy for Malignant Gliomas
84. Supplementary Figure 3 from Recognition and Killing of Autologous, Primary Glioblastoma Tumor Cells by Human Cytomegalovirus pp65-Specific Cytotoxic T Cells
85. Supplementary Figure 6 from Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma
86. Supplementary Figure 2 from Recognition and Killing of Autologous, Primary Glioblastoma Tumor Cells by Human Cytomegalovirus pp65-Specific Cytotoxic T Cells
87. Figure S2 from Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma
88. Supplementary Table 1 from Recognition and Killing of Autologous, Primary Glioblastoma Tumor Cells by Human Cytomegalovirus pp65-Specific Cytotoxic T Cells
89. Supplementary Figure 2 from Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma
90. Supplementary Data from Dysregulation of Glutamate Transport Enhances Treg Function That Promotes VEGF Blockade Resistance in Glioblastoma
91. Supplementary Table 2 from Recognition and Killing of Autologous, Primary Glioblastoma Tumor Cells by Human Cytomegalovirus pp65-Specific Cytotoxic T Cells
92. mRNA challenge predicts brain cancer immunogenicity and response to checkpoint inhibitors
93. mRNA aggregates harness danger response for potent cancer immunotherapy
94. Three-Dimensional Bioconjugated Liquid-Like Solid (LLS) Enhance Characterization of Solid Tumor - Chimeric Antigen Receptor T cell interactions
95. Oral IRAK-4 Inhibitor CA-4948 Is Blood-Brain Barrier Penetrant and Has Single-Agent Activity against CNS Lymphoma and Melanoma Brain Metastases
96. Immunotherapy reverses glioma-driven dysfunction of immune system homeostasis
97. mRNA aggregates harness danger response for potent cancer immunotherapy
98. Three-Dimensional Bioconjugated Liquid-Like Solid (LLS) Enhance Characterization of Solid Tumor - Chimeric Antigen Receptor T cell interactions
99. CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors
100. Emerging trends in immunotherapy for pediatric sarcomas
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.